drugset
drugset / Trial / NCT01586195

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

NCT01586195 ↗

Phase 2 Terminated 31 enrolled Genentech, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, single-agent, phase II study of continuous oral Zelboraf (vemurafenib) in participants with locally-advanced, unresectable, stage IIIc or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.

Timeline

Start
2011-10-31
Primary completion
2015-04-30
Completion
2015-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Vemurafenib Small molecule 960 mg Oral

Indications

melanoma